Clinical Trial Update: UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases [EARLY_Phase 1]

View source ↗

Summary

An early-phase (Phase 1) clinical trial evaluating QT-019C UCAR T-cell therapy targeting CD19/BCMA for relapse or refractory autoimmune diseases, specifically s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Myopathy
• Systemic Lupus Erythematosus

Drugs mentioned

• QT-019C UCAR T-cell therapy (QT-019C UCAR T-cell therapy)

Snippet

Sponsor: The Affiliated Hospital of Xuzhou Medical University | Conditions: Systemic Lupus Erythematosus, Inflammatory Myopathy | EARLY_Phase 1 | Status: NOT_YET_RECRUITING